Drug Profile
Anti-PTHrP vaccine - Pepscan Therapeutics
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Pepscan Systems
- Developer Pepscan Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercalcaemia
Most Recent Events
- 23 May 2012 No development reported - Preclinical for Hypercalcaemia in Netherlands (Parenteral)
- 24 Mar 2009 Preclinical development is ongoing in the Netherlands
- 26 Nov 2007 Preclinical development is ongoing